Imiquimod in Children With Plaque Morphea

Inclusion Criteria: Age at diagnosis 6 to 18 years of age Morphea plaques Female subjects of childbearing potential must have a negative urine pregnancy test Signed consent/assent form Exclusion criteria: Children who received topical corticosteroids, tacrolimus, vitamin D derivatives (calcipotriol, calcipotriol-betamethasone dipropionate) to the affected area in the previous four weeks Children who were previously treated with Imiquimod on the affected areas Children with no demonstrable ultrasonographic changes at the baseline evaluation Children with evidence of skin breakdown on the proposed area to be treated at the time of enrollment due to potential increased absorption of the medication through impaired skin barrier Female subjects of childbearing potential who do not agree to practice effective birth control methods for the duration of the study Children who are/were (in the past 6 months) treated with systemic medications such as methotrexate and/or systemic corticosteroids Co-morbidities: systemic sclerosis, juvenile rheumatoid arthritis, other systemic diseases